Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes, mu, delta and kappa, whose genes have been cloned. Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, in animal models, dopamine D1 receptor knockout rats will not self-administer cocaine37 and μ opioid receptor knockout mice will not show the rewarding effects of opioids.153”
From Neurobiology of addiction: a neurocircuitry analysis (2016) · cites this paper as [153]
In the citing paper
“Mice that lack the MOR gene do not develop place preferences or withdrawal symptoms in response to morphine (Matthes et al 1996).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Matthes et al 1996
Citations
Cites
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., & Hirth, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12048 · Cited by 1,010
Self-citationNeutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.
Roques, B. P., Noble, F., Daugé, V, Fournié-Zaluski, M. C., & Beaumont, A. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00449-1 · Cited by 756
Self-citationLufkin, T., Dierich, A., LeMeur, M., Mark, M., & Chambon, P. (1991) · Cell · doi:10.1016/0092-8674(91)90034-v · Cited by 697
Self-citationChiara, G. D., & Alan North, R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90062-b · Cited by 543
Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M., & Nestler, E. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)91111-d · Cited by 535
A brief history of opiates, opioid peptides, and opioid receptors.
Brownstein, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5391 · Cited by 491
Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
Goldstein, A., & Naidu, A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09190-4 · Cited by 445
Kieffer, B. L. (1995) · Cellular and Molecular Neurobiology · doi:10.1007/bf02071128 · Cited by 389
Self-citationReduction of Morphine Abstinence in Mice with a Mutation in the Gene Encoding CREB
Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J., & Schütz, G. (1996) · Science · doi:10.1126/science.273.5275.657 · Cited by 292
Self-citationThe mouse Pgk-1 gene promoter contains an upstream activator sequence
McBurney, M. W., Sutherland, L. C., Adra, C. N., Leclair, B., Rudnicki, M. A., & Jardine, K. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5755 · Cited by 193
Research works printed but not linked: 9
- Goldstein, A. & Naidu, A. Mol. Pharmacol. 36, 265–272 (1989).
- Pasternak, G. W. Clin. Pharmacol. 16, 1–18 (1993).
- Cowan, A. in Handbook of Experimental Pharmacology Opioids II (ed. Herz, A.) Vol. 104, 393–414 (Springer, Berlin, 1993).
- Roques, B. P., Noble, F., Daugé, V., Fournié-Zaluski, M.-C. & Beaumont, A. Pharmacol. Rev. 45, 87–146 (1993).
- Baamonde, A., Daugé, V., Gacel, C. & Roques, B. P. J. Pharmacol. Exp. Ther. 257, 767–773 (1991).
- Koob, G. F. Trends Biochem. Sci. 13, 177–184 (1992).
- Wei, E. T. J. Pharmacol. Exp. Ther. 216, 12–18 (1981).
- Cowan, A., Zhu, X. Z., Mosberg, H. I., Omnaas, J. R. & Porreca, F. J. Pharmacol. Exp. Ther. 246, 950–955 (1988).
- Kitchen, I. et al. J. Pharmacol. Exp. Ther. 275, 1595–1607 (1995).
Cited by
Items 601–700 of 1,002
The antiallodynic action of pregabalin in neuropathic pain is independent from the opioid system
Kremer, M., Yalçın, İ., Nexon, L., Wurtz, X., Ceredig, R. A., Daniel, D., Hawkes, R. A., Salvat, É., & Barrot, M. (2016) · Molecular Pain · doi:10.1177/1744806916633477 · Cited by 48
TRPV1 is a physiological regulator of μ-opioid receptors
Scherer, P. C., Zaccor, N. W., Neumann, N. M., Vasavda, C., Barrow, R. K., Ewald, A. J., Rao, F., Sumner, C. J., & Snyder, S. H. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717005114 · Cited by 46
Sim‐Selley, L. J., Daunais, J. B., Porrino, L. J., & Childers, S. R. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00344-9 · Cited by 45
Takeda, M., Tanimoto, T., Ikeda, M., Kadoi, J., Nasu, M., & Matsumoto, S. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.02.029 · Cited by 45
Wöhr, M., Moles, A., Schwarting, R. K. W., & D'Amato, F. R. (2011) · Social Neuroscience · doi:10.1080/17470911003765560 · Cited by 45
“Orpm–/– mice were generated by disruption of exon 2 in the Orpm gene as described elsewhere (Matthes et al., 1996).”
BackgroundMethodInfluentialIdentifying pain genes: Bottom-up and top-down approaches
Mogil, J. S., & McCarson, K. E. (2000) · Journal of Pain · doi:10.1054/jpai.2000.9821 · Cited by 49
Sutton, L. P., Ostrovskaya, O. I., Dao, M. T., Xie, K., Orlandi, C., Smith, R. G., Wee, S., & Martemyanov, K. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.026 · Cited by 48
Behavioral architecture of opioid reward and aversion in C57BL/6 substrains
Kirkpatrick, S. L., & Bryant, C. D. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00450 · Cited by 44
“In support, endogenous enkephalins are necessary for NAL-CPA (Skoubis et al., 2005) but not opioidinduced CPP (Marquez et al., 2006) whereas mu opioid receptors are necessary for both phenotypes (Matthes et al., 1996; Skoubis et al., 2001).”
BackgroundGieryk, A., Ziółkowska, B., Solecki, W., Kubik, J., & Przewłocki, R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1730-1 · Cited by 46
“Moreover, enkephalins seem to mediate rewarding effects of drugs of abuse because µ/δ opioid receptor antagonists, genetic knockout of the µ receptor or of the PENK gene, all interfere with reinforcement produced by all classes of addictive substances (e.g., Becker et al. 2000; Berrendero et al. 2002, 2005; Corrigall…”
BackgroundInfluentialPharmacogenetics of Drug Dependence: Role of Gene Variations in Susceptibility and Treatment
Khokhar, J. Y., Ferguson, C. S., Zhu, A. Z. X., & Tyndale, R. F. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105826 · Cited by 48
“Targeted deletion of this gene also helped establish its role in the rewarding effects of morphine (192, 193).”
Mikołajczak, P. Ł., Kędzia, B., Ożarowski, M., Kujawski, R., Bogacz, A., Bartkowiak-Wieczorek, J., Białas, W., Gryszczyńska, A., Buchwald, W., Szulc, M., et al. (2016) · Central European Journal of Immunology · doi:10.5114/ceji.2015.54607 · Cited by 44
“This test is a good model for the study of drugs acting through the central and supramedullary mechanisms of nociception [25, 26].”
MethodFunctional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area
Moreno, E., Quiroz, C., Rea, W. P., Cai, N.-S., Mallol, J., Cortés, A., Lluís, C., Canela, E. I., Casadó, V., & Ferré, S. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2442-16.2016 · Cited by 49
“The -opioid receptor (MOR) is essential for the analgesic and reinforcing effects of opioids (Matthes et al., 1996).”
BackgroundDai, Z., Chu, H., Ma, J., Yan, Y., Zhang, X., & Liang, Y. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00080 · Cited by 45
Koshimizu, T., Honda, K., Nagaoka-Uozumi, S., Ichimura, A., Kimura, I., Nakaya, M., Sakai, N., Shibata, K., Ushijima, K., Fujimura, A., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0144-y · Cited by 51
Daws, S. E., Whittard, J. D., Jacobs, M. M., Ren, Y., Mazloom, A. R., Caputi, F. F., Horváth, M., Keller, É., Ma’ayan, A., Pan, Y., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.012 · Cited by 46
Disruption of the CRF2 Receptor Pathway Decreases the Somatic Expression of Opiate Withdrawal
Papaleo, F., Ghozland, S. G., Ingallinesi, M., Roberts, A. J., Koob, G. F., & Contarino, A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.8 · Cited by 48
Li, H., Kim, J. A., & Whistler, J. L. (2009) · The FASEB Journal · doi:10.1096/fj.09-133223 · Cited by 44
“The effects of morphine are mediated primarily through activation of the -opioid receptor (MOR), as the analgesic, rewarding, and withdrawal-induced aversive effects of morphine are eliminated in mice disrupted for the MOR (1, 2).”
BackgroundWiedenmayer, C. P., & Barr, G. A. (2000) · Behavioral Neuroscience · doi:10.1037//0735-7044.114.1.125 · Cited by 50
Changes in Spinal δ and κ Opioid Systems in Mice Deficient in the A2AReceptor Gene
Bailey, A., Ledent, C. A., Kelly, M., Hourani, S. M. O., & Kitchen, I. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09210.2002 · Cited by 44
Self-citationThe contribution of genetics to addiction therapy approaches
Edenberg, H. J., & Kranzler, H. R. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.011 · Cited by 46
Ren, K., & Dubner, R. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012370880-9.00192-4 · Cited by 49
Sim‐Selley, L. J., Scoggins, K. L., Cassidy, M. P., Smith, L. A., Dewey, W. L., Smith, F. L., & Selley, D. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707328 · Cited by 43
Berrendero, F., Mendizábal, V. E., Murtra, P., Kieffer, B. L., & Maldonado, R. J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02951.x · Cited by 47
Self-citationBohn, L., Gainetdinov, R. R., & Caron, M. G. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:041 · Cited by 50
“…are mediated predominantly via µ opioid receptors (µOR), as suggested by extensive pharmacological studies (for review see Mansour et al., 1995) and also demonstrated by the lack of morphine analgesia observed in knockout mice that are deficient in the µOR (Matthes et al., 1996; Sora et al., 1997).”
BackgroundMarquez, P. V., Baliram, R., Kieffer, B. L., & Lutfy, K. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.01.005 · Cited by 46
“For example, morphine, a mu opioid receptor (MOP) agonist, increases extracellular dopamine in the nucleus accumbens, a response that is thought to play an important role in its rewarding actions (Di Chiara et al., 2004; Matthes et al., 1996; but see Hnasko et al., 2005).”
BackgroundMethodSelf-citationVihavainen, T., Piltonen, M., Tuominen, R. K., Korpi, E. R., & Ahtee, L. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.028 · Cited by 48
“The reinforcing effects of morphine are mediated via µ-opioid receptors (Matthes et al., 1996) and therefore an obvious hypothesis for the mechanism of nicotine–morphine cross-sensitization is that chronic nicotine increases the number of µ-opioid receptors in the brain.”
BackgroundInfluentialCadet, P., Mantione, K. J., Zhu, W. M., Kream, R. M., Sheehan, M., & Stefano, G. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5839 · Cited by 46
Pharmacology of Pediatric Anesthesia
Davis, P. J., Bösenberg, A., Davidson, A. J., Jimenez, N., Kharasch, E. D., Lynn, A. M., Tofovic, S. P., & Woelfel, S. K. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06612-9.00007-9 · Cited by 45
Márki, Á., Monory, K., Ötvös, F., Tóth, G., Kraßnig, R., Schmidhammer, H., Traynor, J. R., Roques, B. P., Maldonado, R. J., & Borsodi, A. D. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00610-x · Cited by 43
Self-citationOlson, G. A., Olson, R. D., & Kastin, A. J. (1997) · Peptides · doi:10.1016/s0196-9781(97)00264-7 · Cited by 49
Ozdemir, D., Allain, F., Kieffer, B. L., & Darcq, E. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109524 · Cited by 49
“Antagonist-precipitated withdrawal in dogs and rodents has been commonly used to induce somatic withdrawal symptoms, verifying the presence of physical dependence (Blasig and Herz, 1977; Frenois et al., 2002; Martin et al., 1974; Matthes et al., 1996; Wikler and Carter, 1953).”
BackgroundSelf-citationThe µ-Opioid Receptor and Treatment Response to Naltrexone
Thorsell, A. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt030 · Cited by 50
“(Matthes et al., 1996).”
BackgroundInfluentialDickenson, A. H., & Kieffer, B. L. (2006) · Elsevier eBooks · doi:10.1016/b0-443-07287-6/50032-1 · Cited by 47
Self-citationExpression of Neural RGS-R7 and Gβ5 Proteins in Response to Acute and Chronic Morphine
López‐Fando, A., Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., & Garzón, J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300515 · Cited by 43
“In the CNS, the actions of morphine are mediated by m-opioid receptors (Matthes et al, 1996).”
BackgroundHain, H. S., Belknap, J. K., & Mogil, J. S. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35124-9 · Cited by 42
“444 at A SPE T Journals on A ugust 17, 2017 jpet.aspetjournals.org nloaded from morphine’s multiple biological actions (Pasternak, 1993; Matthes et al., 1996; Sora et al., 1997).”
Sahraei, H., Ghazzaghi, H., Zarrindast, M., Ghoshooni, H., Sepehri, H., & Haeri-Rohan, A. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.03.004 · Cited by 42
The orphan receptor GPR88 blunts the signaling of opioid receptors and multiple striatal GPCRs
Laboute, T., Gandía, J., Pellissier, L. P., Corde, Y., Rebeillard, F., Gallo, M., Gauthier, C., Léauté, A., Díaz, J., Poupon, A., et al. (2020) · eLife · doi:10.7554/elife.50519 · Cited by 42
Self-citationCussac, D., Rauly‐Lestienne, I., Heusler, P., Finana, F., Cathala, C., Bernois, S., & Vries, L. D. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.04.010 · Cited by 41
Opioid Rotation in Clinical Practice
Nalamachu, S. R. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0051-7 · Cited by 49
Influence of Gz and Gi2 transducer proteins in the affinity of opioid agonists to μ receptors
Garzón, J., Castro, M., & Sánchez‐Blázquez, P. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00267.x · Cited by 41
Aicher, S. A., Schreihofer, A. M., Kraus, J. A., Sharma, S., Milner, T. A., & Guyenet, P. G. (2001) · The Journal of Comparative Neurology · doi:10.1002/cne.1123 · Cited by 41
Wang, W., Xie, X., Zhuang, X., Huang, Y., Tan, T., Gangal, H., Huang, Z., Purvines, W., Wang, X., Stefanov, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112089 · Cited by 45
Malik, S., Khalique, H., Buch, S. J., & Seth, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018116 · Cited by 40
“). Morphine is known to act primarily via mu opioid receptors (MOR)”
BackgroundPharmacogenetics of Opiates in Clinical Practice: the Visible Tip of the Iceberg
Hajj, A., Khabbaz, L. R., Laplanche, J., & Peoc’h, K. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.13 · Cited by 40
Karad, S. N., Pal, M., Crowley, R. S., Prisinzano, T. E., & Altman, R. A. (2017) · ChemMedChem · doi:10.1002/cmdc.201700103 · Cited by 40
Obeng, S., Wang, H., Jali, A. M., Stevens, D. L., Akbarali, H. I., Dewey, W. L., Selley, D. E., & Zhang, Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00349 · Cited by 43
Azmanov, H., Bayatra, A., & Ilan, Y. (2022) · Journal of Pain Research · doi:10.2147/jpr.s356319 · Cited by 43
The rewarding properties of MDMA are preserved in mice lacking µ‐opioid receptors
Robledo, P., Mendizábal, V. E., Ortuño, J., de la Torre, R., Kieffer, B. L., & Maldonado, R. J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03532.x · Cited by 43
“The generation of the knockout mice has been described previously (Matthes et al., 1996).”
MethodSelf-citationBailey, A., Metaxas, A., Al‐Hasani, R., Keyworth, H. L., Forster, D. M., & Kitchen, I. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07104.x · Cited by 42
“In support of this, it has been shown that both heroin and morphine lacked any kind of locomotor stimulation in MOP-r-deficient mice (Matthes et al., 1996; Contarino et al., 2002).”
BackgroundSelf-citationMorphine: A Protective or Destructive Role in Neurons?
Zhang, Y., Chen, Q., & Yu, L. (2008) · The Neuroscientist · doi:10.1177/1073858408314434 · Cited by 41
Congenic C57BL/6 µ opiate receptor (MOR) knockout mice: baseline and opiate effects
Hall, F. S., Li, X. ‐., Goeb, M., Roff, S. R., Hoggatt, H., Sora, I., & Uhl, G. R. (2003) · Genes Brain & Behavior · doi:10.1034/j.1601-183x.2003.00016.x · Cited by 40
“…involving nociceptive, locomotor control and reward systems (Fuchs et al. 1999; Gaveriaux-Ruff et al. 1998; Kitanaka et al. 1998; Loh et al. 1998; Matthes et al. 1996; Roy et al. 1998; Roy et al. 2001; Saria et al. 1997; Sora et al. 1997; Sora et al. 1999; Sora et al. 2001; Ueda et al. 1997).”
BackgroundNeilan, C. L., Nguyen, T. M. ‐., Schiller, P. W., & Pasternak, G. W. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00946-3 · Cited by 40
Drug Binding Poses Relate Structure with Efficacy in the μ Opioid Receptor
Sutcliffe, K. J., Henderson, G., Kelly, E., & Sessions, R. B. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.05.009 · Cited by 39
“It is responsible for both the analgesic and euphoric effects of many opioid drugs [1] and is therefore a protein of very significant clinical and societal importance.”
BackgroundMu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking
Hamida, S. B., Boulos, L., McNicholas, M., Charbogne, P., & Kieffer, B. L. (2017) · Addiction Biology · doi:10.1111/adb.12576 · Cited by 44
“Others and we have demonstrated that rewarding properties of both opiates (Matthes et al. 1996; Roberts et al. 2000; Contet, Kieffer, & Befort 2004) and non-opioid drugs of abuse (Contet et al.”
BackgroundMethodSelf-citationHeteromerization Modulates mu Opioid Receptor Functional Properties in vivo
Ugur, M., Derouiche, L., & Massotte, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01240 · Cited by 47
“Moreover, mu receptors mediate opioid rewarding and euphoric properties that underlie their abuse potential (Matthes et al., 1996).”
BackgroundThe orphan receptor GPR139 signals via Gq/11 to oppose opioid effects
Stoveken, H. M., Zucca, S., Masuho, I., Grill, B. J., & Martemyanov, K. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.014770 · Cited by 43
Vitamin D deficiency exacerbates UV/endorphin and opioid addiction
Kemény, L. V., Robinson, K. C., Hermann, A. L., Walker, D. M., Regan, S., Yew, Y. W., Lai, Y. C., Theodosakis, N., Rivera, P. D., Ding, W., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe4577 · Cited by 42
“Oprm1−/− mice were obtained from the Jackson laboratory (30).”
MethodToddes, C., Lefevre, E. M., Brandner, D. D., Zugschwert, L., & Rothwell, P. E. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2440-20.2021 · Cited by 37
Brain region-specific N-glycosylation and lipid rafts association of the rat mu opioid receptor
Huang, P., Chen, C., Xu, W., Yoon, S.-I., Unterwald, E. M., Pintar, J. E., Wang, Y., Chong, P. L., & Liu‐Chen, L. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.128 · Cited by 41
Zhou, Y., Spangler, R., Schlussman, S. D., Yuferov, V. P., Sora, I., Ho, A., Uhl, G. R., & Kreek, M. J. (2002) · Synapse · doi:10.1002/syn.10101 · Cited by 42
“Investigation of the behavioral effect of morphine reveals that a lack of MOR abolishes analgesic effects of morphine and dramatically reduces morphine self-administration and physical dependence in the MOR-deficient mice (Matthes et al., 1996; Sora et al., 1997; Becker et al., 2000).”
BackgroundMethodResultInfluentialClarke, T., Crist, R. C., Kampman, K. M., Dackis, C. A., Pettinati, H. M., O’Brien, C. P., Oslin, D. W., Ferraro, T. N., Lohoff, F. W., & Berrettini, W. H. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.02.018 · Cited by 41
“Mice lacking MOR have abolished therapeutic responses to opioids and display attenuated reward responses to cocaine [4, 16, 27].”
BackgroundYoo, J., Lee, S., Loh, H. H., Ho, I. K., & Jang, C. (2004) · Synapse · doi:10.1002/syn.20067 · Cited by 46
“…laboratories have reported upon the generation of -opioid receptor knockout mice following deletion of exon 1 (Tian et al., 1997; Schuller et al., 1999; Sora et al., 1997), the insertion of a Neo cassette in exon 2 (Matthes et al., 1996), or the deletion of both exons 2 and 3 (Loh et al., 1998).”
BackgroundMethodInfluentialWalwyn, W. M., Maidment, N. T., Sanders, M. J., Evans, C. J., Kieffer, B. L., & Hales, T. G. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014829 · Cited by 44
“Dorsal root ganglia were harvested from early postnatal mice (postnatal days 0–2), which contained one ( / ), both ( / ), or neither ( / ) receptor alleles in the C57BL/6 background (Matthes et al., 1996).”
BackgroundSelf-citationGalanin – 25 years with a multitalented neuropeptide: Galanin and addiction
Picciotto, M. R. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8151-x · Cited by 44
Morphine tolerance and dependence in the nociceptin receptor knockout mice
Mamiya, T., Noda, Y., Ren, X., Nagai, T., Takeshima, H., Ukai, M., & Nabeshima, T. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100012 · Cited by 42
“Receptor binding assay was performed according to the previous reports (Ilien et al., 1988; Matthes et al., 1996 ).”
MethodAguila, B., Coulbault, L., Boulouard, M., Lιveillι, F., Davis, A., Tσth, G., Borsodi, A. D., Balboni, G., Salvadori, S., Jauzac, P., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707497 · Cited by 41
“Using knockout (KO) mice, m-opioid (MOP) receptors were described as the mediators of morphine-induced analgesia (Matthes et al., 1996).”
BackgroundAzuma, Y., & Ohura, K. (2002) · Inflammation · doi:10.1023/a:1019766602138 · Cited by 42
“On the other hand, the m-opioid receptor mediates the effect of morphine as well as the actions of endogenous opioid ligands involved in diverse functions in the central and peripheral nervous systems ( 1 ).”
BackgroundSexual receptivity is reduced in the female mu-opioid receptor knockout mouse
Sinchak, K., Shahedi, K., Dewing, P., & Micevych, P. E. (2005) · Neuroreport · doi:10.1097/01.wnr.0000181585.49130.93 · Cited by 38
Cuesta, J., Burokas, A., Mancino, S., Kummer, S., Martín‐García, E., & Maldonado, R. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.149 · Cited by 42
“Homozygous knockout mice deficient in MOR, DOR, PENK and PDYN on a C57BL/6J background and their respective wild-type littermates were used (Matthes et al, 1996; Filliol et al, 2000; König et al, 1996; Galeote et al, 2009).”
MethodSelf-citationAutism Spectrum Disorders and Drug Addiction: Common Pathways, Common Molecules, Distinct Disorders?
Rothwell, P. E. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00020 · Cited by 42
“The mu opioid receptor (MOR) is a particularly critical mediator of the rewarding effects of opiates like morphine (Matthes et al., 1996).”
BackgroundThe role of cyclin-dependent kinase 5 in neuropathic pain
Gómez, K., Vallecillo, T., Moutal, A., Perez‐Miller, S., Delgado‐Lezama, R., Felix, R., & Khanna, R. (2020) · Pain · doi:10.1097/j.pain.0000000000002027 · Cited by 36
Mu‐opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia
Bohren, Y., Karavelic, D., Tessier, L., Yalçın, İ., Gavériaux‐Ruff, C., Kieffer, B. L., Freund‐Mercier, M. J., & Barrot, M. (2009) · European Journal of Pain · doi:10.1016/j.ejpain.2009.11.014 · Cited by 42
“In MOR-deficient mice, morphine analgesia was thus abolished (Matthes et al., 1996; Sora et al., 1997, 1999; Fuchs et al., 1999; Schuller et al., 1999; Qiu et al., 2000) or strongly reduced (Loh et al., 1998) in models of thermal (Matthes et al., 1996; Sora et al., 1997; Loh et al., 1998; Schuller…”
InfluentialSelf-citationSanchis‐Segura, C., Grisel, J. E., Olive, M. F., Ghozland, S., Koob, G. F., Roberts, A. J., & Cowen, M. S. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000174913.60384.e8 · Cited by 38
Raehal, K. M., Schmid, C. L., Medvedev, I. O., Gainetdinov, R. R., Premont, R. T., & Bohn, L. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.011 · Cited by 43
“Numerous pharmacological and knockout mouse studies have demonstrated that the physiological and behavioral effects of morphine are mediated primarily through activation of the mu-opioid receptor (μOR) (Matthes et al., 1996; Sora et al., 1997; Roy et al., 1998; Kieffer et al., 1999).”
BackgroundMorphine Tolerance in Spinal Cord Is Due to Interaction between μ- and δ-Receptors
Riba, P., Ben, Y., Smith, A. P., Fürst, S., & Lee, N. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.265 · Cited by 38
“A preponderance of evidence indicates that opioid antinociception is mediated via the -receptor (Fang et al., 1986; Matthes et al., 1996; Sora et al., 1997), although - and -receptors can also mediate this effect in at least some central nervous system locations and some antinociceptive tests…”
BackgroundRademacher, D. J., & Steinpreis, R. E. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00950-3 · Cited by 39
García-Sevilla, J. A., Ventayol, P., Busquets, X., Harpe, R. L., Walzer, C., & Guimón, J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00227-9 · Cited by 41
Post-transcriptional regulation of mouse kappa-opioid receptor expression.
Wei, L., Hu, X., Bi, J., & Loh, H. H. (2000) · PubMed · Cited by 38
Bedene, A., Dahan, A., Rosendaal, F. R., & van Dorp, E. L. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2114898 · Cited by 46
Activation ofμopioid receptors modulates inflammation in acute experimental colitis
Anselmi, L., Huynh, J., Duraffourd, C. C., Jaramillo, I., Vegezzi, G., Saccani, F., Boschetti, E., Brecha, N. C., GIORGIO, R. D., & Sternini, C. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12521 · Cited by 41
Walwyn, W. M., John, S., Maga, M., Evans, C. J., & Hales, T. G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055913 · Cited by 42
Moore, K., Madularu, D., Iriah, S. C., Yee, J. R., Kulkarni, P. P., Darcq, E., Kieffer, B. L., & Ferris, C. F. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00471 · Cited by 39
“Indeed, MuKO mice showed lack of morphine analgesia, rewarding effect and physical dependence, indicating that a single receptor mediates all biological effects of the prototypic opiate (Matthes et al., 1996).”
BackgroundMethodSelf-citationBlockade of neuronal dopamine D2 receptor attenuates morphine tolerance in mice spinal cord
Dai, W., Xiong, F., Yan, B., Cao, Z., Liu, W., Liu, J.-H., & Yu, B. (2016) · Scientific Reports · doi:10.1038/srep38746 · Cited by 43
Neurobiology of drug addiction.
Koob, G. F., Caine, S. B., Hyytiä, P., Markou, A., Parsons, L. H., Roberts, A. J., Schulteis, G., & Weiss, F. (1999) · American Psychological Association eBooks · doi:10.1037/10341-008 · Cited by 41
Riley, M. A., & Vathy, I. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.022 · Cited by 38
Moulédous, L., Neasta, J., Uttenweiler‐Joseph, S., Stella, A., Matondo, M., Corbani, M., Monsarrat, B., & Meunier, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013391 · Cited by 40
“a recombinant human neuroblastoma SH-SY5Y clone (sc2) stably over-expressing the MOP receptor, the principal if not exclusive vector of acute and chronic morphine actions in vivo (Matthes et al., 1996).”
Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions
Maher, C. E., Selley, D. E., & Childers, S. R. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00272-0 · Cited by 39
KO, J. L., & Loh, H. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004279200 · Cited by 39
A molecular basis for opiate action
Massotte, D., & Kieffer, B. L. (1998) · Essays in Biochemistry · doi:10.1042/bse0330065 · Cited by 37
Self-citationGene disruption in mice: Models of development and disease
Shastry, B. S. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006865210012 · Cited by 41
Synthesis and evaluation of new endomorphin analogues modified at the Pro2 residue
Torino, D., Mollica, A., Pinnen, F., Lucente, G., Feliciani, F., Davis, P., Lai, J. Y., Ma, S.-W., Porreca, F., & Hruby, V. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.008 · Cited by 36
Abdyazdani, N., Nourazarian, A., Charoudeh, H. N., Kazemi, M., Feizy, N., Akbarzade, M., Mehdizadeh, A., Rezaie, J., & Rahbarghazi, R. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.025 · Cited by 36
Liao, J., & Wang, Y. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1422025 · Cited by 41
“The most powerful analgesic and addictive properties of opiate alkaloids are mediated by the Mu opioid receptor (MOR) (Matthes et al., 1996).”
BackgroundKatsuura, Y., & Taha, S. A. (2009) · Neuropeptides · doi:10.1016/j.npep.2009.12.002 · Cited by 36
“Cooperative interactions of MOR and DOR signaling are also supported by studies of nociception in MOR knockout mice, as the analgesic effects of DOR agonists are absent or attenuated in these animals (Matthes et al., 1996; Sora et al., 1999; Gaveriaux-Ruff and Kieffer, 2002).”
Huang, P., Xu, W., Yoon, S.-I., Chen, C., Chong, P. L., Unterwald, E. M., & Liu‐Chen, L. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.096 · Cited by 36
“Morphine acts primarily on the MOR (Matthes et al., 1996) and is among the most widely used and abused drugs.”
BackgroundDiaz, S. L., Barros, V. G., Antonelli, M. C., Rubio‐Terres, C., & Balerio, G. N. (2006) · Synapse · doi:10.1002/syn.20279 · Cited by 39
“In particular, the opioid antagonist naloxone (NAL) failed to induce any withdrawal classical sign in MOR-dependent mice lacking the l-opioid receptor gene (Matthes et al., 1996).”
BackgroundHummel, M., Ansonoff, M. A., Pintar, J. E., & Unterwald, E. M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.01.025 · Cited by 40
Structural Basis for μ-Opioid Receptor Binding and Activation
Serohijos, A. W. R., Yin, S., Ding, F., Gauthier, J., Gibson, D. G., Maixner, W. D., Dokholyan, N. V., & Diatchenko, L. B. (2011) · Structure · doi:10.1016/j.str.2011.08.003 · Cited by 39
“MOR receptors in the peripheral and central nervous system are the primary target of exogenous opioid analgesics (Matthes et al., 1996; Reisine et al., 1996; Sora et al., 1997; Uhl et al., 1999).”
Regulation of Mouse κ Opioid Receptor Gene Expression by Retinoids
Bi, J., Hu, X., Loh, H. H., & Wei, L. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01590.2001 · Cited by 38
“In knock-out animal models, it has been shown that opioid receptors mediate the pharmacological and toxic effects of morphine, as well as certain animal behaviors ( Matthes et al., 1996; Sora et al., 1997; Tian et al., 1997; Loh et al., 1998; Simonin et al., 1998).”
BackgroundEndomorphins and related opioid peptides
Okada, Y., Tsuda, Y., Bryant, S. D., & Lazarust, L. H. (2002) · Vitamins and hormones · doi:10.1016/s0083-6729(02)65067-8 · Cited by 42
Metadata
- Authors
- Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B. P., & Kieffer, B. L.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Surrey (GB)
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- Inserm (FR)
- Venue
- Nature
- Published
- 1996-10
- Volume
- 383
- Issue
- 6603
- Pages
- 819-823
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051746492
- Cited by
- 1,722
- References
- 25
- Citations by year
- 2026: 36 · 2025: 40 · 2024: 45 · 2023: 52 · 2022: 53 · 2021: 56 · 2020: 59 · 2019: 56 · 2018: 53 · 2017: 43 · 2016: 59 · 2015: 53 · 2014: 60 · 2013: 65 · 2012: 58
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- mu-opioid receptor, morphine, analgesia, opioid reward, place preference, opioid withdrawal, physical dependence, knockout mice, delta opioid receptor, kappa opioid receptor, opioid system, pain management
- MeSH terms
- Analgesics, Animals, Behavior, Animal, Cell Line, Enkephalins, Mice, Inbred C57BL, Morphine, Morphine Dependence, Narcotics, Reward, Substance Withdrawal Syndrome, Gene Deletion, Receptors, Opioid, mu, Receptors, Opioid, delta, Receptors, Opioid, kappa, Mice, Knockout, Enkephalin, Ala(2)-MePhe(4)-Gly(5)-, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.